Cocrystal Corporate Overview

February 18, 2020

Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds

Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market